Background: This meta-analysis aimed to assess the cardiac safety profile of domperidone treatment for the risk of cardiovascular (CV) event and QT prolongation. Methods: Data from nine studies involving 101,155 patients were used for the analysis of CV event risk, while data from eight studies involving 390 patients were used for the analysis of QT prolongation risk. Results: Meta-analysis findings suggested a significant increase in CV risk under domperidone as compared to no treatment for domperidone doses of >30 mg/day (OR: 3.14, 95% CI, 1.191 to 8.304, p ¼ 0.021), no significant increase in QT prolongation event rates with domperidone (3.54%, 95% CI, 1.73% to 7.10%) and a significantly lower CV risk for domperidone than for metoclopramide (OR: 0.63, 95% CI, 0.58 to 0.70, p < 0.001). Conclusions: The present meta-analysis indicates that domperidone treatment may not be associated with an overall CV event risk increase at doses 30 mg/day and does not result in QT prolongation.

Background: Warfarin is highly efficacious in reducing stroke risk in patients with atrial fibrillation (AF). However, its safety and efficacy in stroke prevention is markedly influenced by its time in therapeutic range (TTR (40.3 ± 18 vs. 46.9 ± 19, respectively, p < 0.001). Death, cardiac hospitalization and minor bleeding rates were higher in the group with TTR value < 40% than the group with > 40% (3.4% vs. 5.9%; 28.6% vs. 35.4%; 36.5% vs. 41.7%, respectively, all of them p < 0.001). A correlation analysis showed a negative correlation between age and TTR value (r = -0.178, p < 0.001 non-valvular AF patients. (Cardiol J 2015; 22, 5: 567-575)

No abstract

No abstract

Introduction: Numerous studies showed that higher body mass index (BMI) is associated with better survival in hemodialysis (HD) patients. Most of them evaluated short‐term mortality. It has been suggested that presence of inflammation may be a key modifier of relationship between BMI and mortality in incident HD patients. We examined whether presence of inflammation modifies the association between BMI and mortality in both short‐term and long‐term follow‐up in a large group of prevalent HD patients. Methods: A total of 3.252 HD patients from 41 HD centers were enrolled; the patients were divided into quartiles based on time‐averaged BMI (Q1 < 21.5, Q2 21.5 to <24.3, Q3 24.3 to <27.4, Q4 ≥ 27.4 kg/m2). Inflammation status was defined as present (inflamed) (C‐reactive protein (CRP) ≥1.0 mg/dL and/or serum albumin ≤3.5 g/dL) or absent (noninflamed). Findings: During 7 years of follow‐up 1386 patients (42.6%) died. Compared to noninflamed patients, inflamed patients in the lowest BMI quartile showed 5‐fold increased risk for mortality in the short‐term (95% confidence interval [CI] 2.82–9.22, P < 0.001) and 3‐fold in the long‐term (95%CI 2.42–4.27, P < 0.001) compared to the highest BMI quartile. Whereas, inflamed patients in the highest BMI quartile experienced 2‐fold increased risk in short‐term (95%CI 1.17–3.74, P = 0.01) and 1.68‐fold increased risk in long‐term (95%CI 1.30–2.18, P < 0.001) than in noninflamed patients. The protective effect of BMI for overall mortality was present in all age groups, in both genders, in patient with and without diabetes. BMI was not a mortality predictor in patients with HD duration more than 76 months at baseline. The protective effect of BMI was observed in all albumin tertiles. In patients in the lowest CRP tertile, BMI was not associated with mortality. Discussion: Higher BMI is associated with lower short‐term and long‐term mortality risk, especially in patients with inflammation in a prevalent HD population.